Kessler Promises Cancer Patient Liaison In FDA; Considers Joint Drugs, Biologics Oncology Review
In Brief: Painter Is AMA President-Elect; FDA Approves Taxol; Protocol Enrolls 150-200 A Month
FDA’s Commitment To Cancer No Different Than Other Diseases, Kessler Tells Advocate
FDA Officials Lists ‘Lessons’ Learned Working With AIDS Patient Organizations
FDA Lacks Resources To Deal With Onslaught Of New Cancer Drugs, Friedman Tells Agency
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”









